Doctors Note Logo

Published on: 11/9/2026

Biphasic Anaphylaxis: Why Secondary Systemic Rebound Occurs Hours After the Initial Epinephrine Dose

Biphasic anaphylaxis is a second surge of systemic allergic symptoms that strikes after the first reaction appears fully resolved, most often 4 to 12 hours later but possibly up to 72 hours, and it happens because injected epinephrine wears off in roughly 10 to 20 minutes while late-phase inflammatory cells, newly synthesized mediators, and residual allergen in the gut or tissues keep driving mast cell and basophil activation. Known risk factors include delayed or insufficient epinephrine, needing more than one dose, severe or hypotensive initial symptoms, an unknown trigger, and oral or food-based exposures, which is why observation periods and a second auto-injector matter. Important nuances about warning signs, monitoring windows, and when the rebound is more likely to be severe are covered below, so review the complete answer rather than this summary alone.

Because a returning wave of hives, throat tightness, vomiting, wheezing, or lightheadedness can escalate quickly and is easy to mistake for anxiety or a lingering first reaction, getting a fast read on your symptoms helps you decide whether to use epinephrine again and call emergency services now. Take a free, instant, online symptom check to clarify what your current symptoms may indicate and what step to take next.

Last reviewed for medical accuracy: 11/09/2026

answer background

Concerned about your symptoms?

Explanation

Biphasic Anaphylaxis: Why a Secondary Systemic Rebound Can Occur Hours After the Initial Epinephrine Dose

Biphasic anaphylaxis is a second episode of anaphylaxis that develops after the first episode has improved or completely resolved, without a new exposure to the original trigger. It can occur several hours after treatment, including after an initial dose of epinephrine appeared to work.

This delayed reaction is uncommon, but it is medically important. Anyone with possible anaphylaxis should receive urgent medical assessment, even if symptoms improve after epinephrine.

What happens during anaphylaxis?

Anaphylaxis is a rapid, whole-body allergic or hypersensitivity reaction. It can affect the skin, breathing, heart and blood circulation, stomach and intestines, and nervous system.

During a reaction, immune cells such as mast cells and basophils release powerful chemical mediators, including histamine, tryptase, leukotrienes, and prostaglandins. These substances can cause:

  • Swelling of the lips, tongue, throat, or other tissues
  • Wheezing, coughing, chest tightness, or difficulty breathing
  • Widespread hives, flushing, itching, or skin redness
  • Vomiting, abdominal pain, or diarrhea
  • Dizziness, fainting, confusion, or collapse
  • A dangerous fall in blood pressure

Epinephrine is the first-line treatment for anaphylaxis because it rapidly supports blood pressure, relaxes airway muscles, reduces swelling, and helps limit the release of additional inflammatory mediators. However, epinephrine does not remain active in the body for a long time. Its effects may wear off while the underlying immune response is still active.

What is biphasic anaphylaxis?

In biphasic anaphylaxis, the initial symptoms improve after treatment, but similar or new symptoms return later. The second phase occurs without another clear exposure to the allergen.

The second episode may be milder than the first, but it can also be serious. It may involve breathing problems, low blood pressure, or swelling of the airway. A person should not assume that a second wave is “just anxiety,” indigestion, or a side effect of epinephrine.

Research and clinical guidelines report different rates because studies use different definitions and follow-up periods. Modern evidence suggests that biphasic reactions occur in a minority of anaphylaxis cases—often estimated at roughly 5% or less—but the risk is higher after severe or poorly controlled reactions. Most delayed reactions happen within several hours, although later recurrence has been reported.

Why can symptoms return after epinephrine?

The exact biological mechanism is not fully understood. A biphasic reaction is probably not caused by one single process. Several explanations may contribute.

1. Inflammatory chemicals may continue to be released

Epinephrine can quickly reverse the effects of anaphylaxis, but it may not completely stop mast cells and basophils from releasing mediators. The immune response can continue at a lower level and then become clinically noticeable again after the initial improvement.

This is one reason a person may feel better temporarily and then develop swelling, wheezing, hives, vomiting, or dizziness later.

2. The original trigger may still be present in the body

Some allergens are absorbed gradually, particularly food allergens. Digestion and continued absorption from the gastrointestinal tract may expose the immune system to more of the trigger over time.

In other situations, a medication may remain in the bloodstream or tissues, or an insect sting may continue to cause local absorption of venom. This does not necessarily mean a new exposure occurred. It may reflect continued exposure from the original event.

3. The first episode may not have been fully controlled

A delayed or inadequate initial dose of epinephrine can allow the reaction to progress before treatment takes effect. Severe anaphylaxis may also require repeated doses, intravenous fluids, oxygen, or other hospital-based treatment.

If the first episode was only temporarily suppressed, symptoms may return as the effect of epinephrine decreases. This is sometimes described as “rebound,” but it is not usually a withdrawal reaction to epinephrine. It more likely reflects ongoing or reactivated anaphylaxis.

4. The immune response may have a second phase

Anaphylaxis involves complex interactions among immune cells, blood vessels, airway tissues, and inflammatory chemicals. The early phase may cause sudden symptoms, while later inflammatory signaling contributes to renewed symptoms.

This proposed “two-phase” process is one reason biphasic reactions can occur even when the original trigger is no longer entering the body. However, the precise mechanism remains an area of medical research.

Who may have a higher risk?

No one can predict with certainty who will develop biphasic anaphylaxis. Clinical guidance from organizations such as the World Allergy Organization, the American Academy of Allergy, Asthma & Immunology, and the Resuscitation Council UK identifies several features associated with greater risk:

  • A severe initial reaction, especially low blood pressure or breathing failure
  • Delayed administration of epinephrine
  • The need for more than one epinephrine dose
  • Persistent symptoms despite initial treatment
  • A large or continuing exposure to the trigger
  • An unknown trigger
  • A history of severe anaphylaxis
  • Significant asthma or other serious respiratory disease

These are risk factors, not predictions. A mild-looking first reaction can occasionally worsen, and a severe reaction does not always become biphasic.

What should you do if symptoms return?

A return of breathing, circulation, throat, or whole-body symptoms after an initial improvement should be treated as a medical emergency.

If anaphylaxis is suspected:

  • Use an epinephrine auto-injector immediately, following the device instructions and the person’s emergency plan.
  • Call emergency services, or have someone call while epinephrine is given.
  • If symptoms do not improve or return, a second dose may be needed if available and permitted by the prescribed plan or local emergency guidance.
  • Lie down with the legs raised if possible. If breathing is difficult, sit with the upper body raised; do not stand or walk.
  • If vomiting or unconsciousness is present, place the person on their side while maintaining the airway.
  • Do not rely on antihistamines, inhalers, or corticosteroids instead of epinephrine. These treatments may help selected symptoms, but they do not reliably reverse dangerous airway swelling or low blood pressure.
  • Avoid food, drink, or further exposure to the suspected trigger until medical professionals advise otherwise.

Anyone who has used epinephrine for suspected anaphylaxis should be medically evaluated. Symptoms can recur, and observation time should be individualized according to the severity of the reaction, treatment required, and risk factors. There is no single observation period that completely guarantees a biphasic reaction will not occur.

Does epinephrine cause the second reaction?

Current evidence does not support the idea that epinephrine causes biphasic anaphylaxis. Epinephrine is the recommended first-line treatment and can be lifesaving. Temporary effects such as shaking, rapid heartbeat, headache, pallor, or anxiety are common after epinephrine and usually wear off.

Those effects are different from renewed anaphylaxis. Trouble breathing, throat swelling, faintness, persistent vomiting, widespread hives with other symptoms, or signs of poor circulation require urgent medical attention.

After recovery, a doctor or allergy specialist can help identify possible triggers, review how the reaction was treated, prescribe or renew epinephrine auto-injectors, and create a written emergency plan. Testing may be appropriate, but it should be arranged by a qualified clinician rather than performed during the acute emergency.

For general symptom guidance, you might consider a free, online symptom check, using the doctor approved Ubie Symptom Checker. It cannot diagnose anaphylaxis or replace emergency care. If anything could be life-threatening or serious—or if you are unsure—speak to a doctor or contact emergency services immediately.

Medical basis: This explanation reflects guidance and evidence from the World Allergy Organization anaphylaxis guidance, the Resuscitation Council UK emergency guidelines, American allergy and immunology practice guidance, and systematic reviews of biphasic anaphylaxis.

(References)

  • * Reingardiene D. [The consequence of epinephrine (adrenaline) overdose]. Medicina (Kaunas). 2006;42(7):606-9. PMID: 16861845.

  • * Shaker MS, Wallace DV, Golden DBK, Oppenheimer J, Bernstein JA, Campbell RL, Dinakar C, Ellis A, Greenhawt M, Khan DA, Lang DM, Lang ES, Lieberman JA, Portnoy J, Rank MA, Stukus DR, Wang J, Collaborators, Riblet N, Bobrownicki AMP, Bontrager T, Dusin J, Foley J, Frederick B, Fregene E, Hellerstedt S, Hassan F, Hess K, Horner C, Huntington K, Kasireddy P, Keeler D, Kim B, Lieberman P, Lindhorst E, McEnany F, Milbank J, Murphy H, Pando O, Patel AK, Ratliff N, Rhodes R, Robertson K, Scott H, Snell A, Sullivan R, Trivedi V, Wickham A, Chief Editors, Shaker MS, Wallace DV, Workgroup Contributors, Shaker MS, Wallace DV, Bernstein JA, Campbell RL, Dinakar C, Ellis A, Golden DBK, Greenhawt M, Lieberman JA, Rank MA, Stukus DR, Wang J, Joint Task Force on Practice Parameters Reviewers, Shaker MS, Wallace DV, Golden DBK, Bernstein JA, Dinakar C, Ellis A, Greenhawt M, Horner C, Khan DA, Lieberman JA, Oppenheimer J, Rank MA, Shaker MS, Stukus DR, Wang J. Anaphylaxis-a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis. J Allergy Clin Immunol. 2020 Apr;145(4):1082-1123. doi: 10.1016/j.jaci.2020.01.017. Epub 2020 Jan 28. PMID: 32001253.

  • * Pflipsen MC, Vega Colon KM. Anaphylaxis: Recognition and Management. Am Fam Physician. 2020 Sep 15;102(6):355-362. PMID: 32931210.

  • * Tanno LK, Demoly P. Anaphylaxis in children. Pediatr Allergy Immunol. 2020 Nov;31 Suppl 26:8-10. doi: 10.1111/pai.13336. PMID: 33236416.

  • * McHugh K, Repanshek Z. Anaphylaxis: Emergency Department Treatment. Emerg Med Clin North Am. 2022 Feb;40(1):19-32. doi: 10.1016/j.emc.2021.08.004. Epub 2021 Oct 29. PMID: 34782088.

  • * Motosue MS, Li JT, Campbell RL. Anaphylaxis: Epidemiology and Differential Diagnosis. Immunol Allergy Clin North Am. 2022 Feb;42(1):13-25. doi: 10.1016/j.iac.2021.09.010. PMID: 34823743.

  • * Navalpakam A, Thanaputkaiporn N, Poowuttikul P. Management of Anaphylaxis. Immunol Allergy Clin North Am. 2022 Feb;42(1):65-76. doi: 10.1016/j.iac.2021.09.005. PMID: 34823751.

  • * McHugh K, Repanshek Z. Anaphylaxis: Emergency Department Treatment. Immunol Allergy Clin North Am. 2023 Aug;43(3):453-466. doi: 10.1016/j.iac.2022.10.002. PMID: 37394252.

  • * Dribin TE, Muraro A, Camargo CA Jr, Turner PJ, Wang J, Roberts G, Anagnostou A, Halken S, Liebermann J, Worm M, Zuberbier T, Sampson HA, GA(2)LEN Anaphylaxis Study Team. Anaphylaxis definition, overview, and clinical support tool: 2024 consensus report-a GA(2)LEN project. J Allergy Clin Immunol. 2025 Aug;156(2):406-417.e6. doi: 10.1016/j.jaci.2025.01.021. Epub 2025 Jan 27. PMID: 39880313; PMCID: PMC12301991.

  • * Wallace DV, Hossny EM, Levin M, Munblit D, Turner PJ. Anaphylaxis Guidelines. Immunol Allergy Clin North Am. 2026 May;46(2):233-256. doi: 10.1016/j.iac.2026.01.007. Epub 2026 Mar 4. PMID: 41932745.

Tell your friends about us.

We would love to help them too.

smily Shiba-inu looking

For First Time Users

What is Ubie’s Doctor’s Note?

We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.

Was this page helpful?

Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.